COMPANY

Alto Neuroscience, Inc.

HQ: Mountain View, CA source · altoneuroscience.com ↗ · West Coast

Keywords: small molecule psychiatry bipolar disorder transdermal schizophrenia cognitive impairment neurology Major Depressive Disorder depression Treatment-resistant Depression Anhedonia Bipolar Disorder I or II With a Major Depressive Episode Post Traumatic Stress Disorder ALTO-100 ALTO-207 ALTO-203 ALTO-101 ALTO-101 Transdermal Delivery System ALTO-300

Location: Mountain View, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

12Trials (company is sponsor)6NIH grants

Funding and NIH signals

SEC Form D raise Raised $50M (Form D filed Oct 27, 2025). SEC Form D 0001231919-25-000357 (Oct 27, 2025)
Evidence (1 event)
- Oct 27, 2025 · SEC Form D 0001231919-25-000357
  Name of Issuer: Alto Neuroscience, Inc.; CIK: 1999480; Address: Mountain View, CA; Submission type: D; Filing date: 2025-10-27; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 49999533; Total Amount Sold: 49999533; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

2026-05 Trial start Phase 2: ALTO-207 in Adults With Treatment-resistant Depression (TRD) source ↗
Oct 2, 2024 Trial start Phase 2: ALTO-100 in Bipolar Disorder With Depression (BD-D) source ↗
Jun 11, 2024 Trial start Phase 2: Study of ALTO-101 in Patients With Schizophrenia source ↗
Mar 25, 2024 Trial start Phase 2: PD, PK, and Safety of ALTO-203 in Patients With MDD source ↗
Jun 8, 2023 Trial start Phase 2: Study of ALTO-300 in MDD source ↗
Jan 10, 2023 Trial start 2: Phase 2b Study of ALTO-100 in MDD source ↗
Jun 1, 2022 Trial start Phase 2: Pilot Decentralized Trial source ↗
Feb 3, 2022 Trial start Phase 2: ALTO-300 in Depression (ALTO-300-004) source ↗
Dec 20, 2021 Trial start Phase 2: ALTO-100 in MDD and/or PTSD source ↗
Dec 13, 2021 Trial start Phase 2: ALTO-300 in Depression source ↗
Oct 15, 2020 Trial start Phase 4: Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram source ↗
Oct 15, 2020 Trial start Phase 4: Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 2 · Study of ALTO-300 in MDD · NCT05922878
2027-11 (ESTIMATED) · Phase 2 · ALTO-207 in Adults With Treatment-resistant Depression (TRD) · NCT07553637

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 12

Record	Title	Phase	Status	Start	Primary completion
NCT07553637	ALTO-207 in Adults With Treatment-resistant Depression (TRD)	Phase 2	Recruiting	2026-05	2027-11 (estimated)
NCT06391593	PD, PK, and Safety of ALTO-203 in Patients With MDD	Phase 2	Completed	Mar 25, 2024	Apr 14, 2025 (actual)
NCT06502964	Study of ALTO-101 in Patients With Schizophrenia	Phase 2	Recruiting	Jun 11, 2024	2026-02 (estimated)
NCT05712187	Phase 2b Study of ALTO-100 in MDD	2	Completed	Jan 10, 2023	Sep 5, 2024 (actual)
NCT05922878	Study of ALTO-300 in MDD	Phase 2	Recruiting	Jun 8, 2023	2026-12 (estimated)
NCT06656416	ALTO-100 in Bipolar Disorder With Depression (BD-D)	Phase 2	Recruiting	Oct 2, 2024	2026-08 (estimated)
NCT05118750	ALTO-300 in Depression	Phase 2	Completed	Dec 13, 2021	May 5, 2023 (actual)
NCT05157945	ALTO-300 in Depression (ALTO-300-004)	Phase 2	Completed	Feb 3, 2022	Apr 26, 2023 (actual)
NCT05419869	Pilot Decentralized Trial	Phase 2	Completed	Jun 1, 2022	Jan 13, 2023 (actual)
NCT05117632	ALTO-100 in MDD and/or PTSD	Phase 2	Completed	Dec 20, 2021	Dec 1, 2022 (actual)
NCT04388202	Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram	Phase 4	Withdrawn	Oct 15, 2020	May 30, 2023 (estimated)
NCT04388189	Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion	Phase 4	Withdrawn	Oct 15, 2020	May 30, 2023 (estimated)

NIH awards 6

Annual award amounts. Total $6.2M.

Jan 31, 2022 NIH award 5R44MH123373-03 FY2022: $1,016,513 awarded for that fiscal year; activity R44 (SBIR); PI ETKIN, AMIT; recipient as written: ALTO NEUROSCIENCE, INC., Los Altos, CA. Validating of Machine Learning-Based EEG T source ↗
Jul 21, 2021 NIH award 5DP1MH116506-06 FY2021: $1,015,000 awarded for that fiscal year; activity DP1 (OTHER_NIH); PI ETKIN, AMIT; recipient as written: ALTO NEUROSCIENCE, INC., Los Altos, CA. A "Circuits-First" Platform for Perso source ↗
Mar 5, 2021 NIH award 5R44MH123373-02 FY2021: $1,184,093 awarded for that fiscal year; activity R44 (SBIR); PI ETKIN, AMIT; recipient as written: ALTO NEUROSCIENCE, INC., Los Altos, CA. Validating of Machine Learning-Based EEG T source ↗
Jul 10, 2020 NIH award 5DP1MH116506-05 FY2020: $931,000 awarded for that fiscal year; activity DP1 (OTHER_NIH); PI ETKIN, AMIT; recipient as written: ALTO NEUROSCIENCE, INC., Los Altos, CA. A "Circuits-First" Platform for Persona source ↗
Feb 28, 2020 NIH award 1R44MH123373-01 FY2020: $988,093 awarded for that fiscal year; activity R44 (SBIR); PI ETKIN, AMIT; recipient as written: ALTO NEUROSCIENCE, INC., Los Altos, CA. Validating of Machine Learning-Based EEG Tre source ↗
Nov 26, 2019 NIH award 7DP1MH116506-04 FY2019: $1,099,000 awarded for that fiscal year; activity DP1 (OTHER_NIH); PI ETKIN, AMIT; recipient as written: ALTO NEUROSCIENCE, INC., Los Altos, CA. A "Circuits-First" Platform for Perso source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-10-27 Raise Private raise (SEC Form D): $50.0M sold; issuer “Alto Neuroscience, Inc.”. Verified from the SEC filing. SEC filing ↗